Medical Billing Services in Maryland

The page covers claims management, denial management, eligibility and authorization support, payment reconciliation, aging accounts receivable follow-up, contract compliance review, revenue-cycle consulting, and workflow improvement. These areas reflect the billing complexity of infectious disease practices that may manage office visits, hospital consults, infusion services, OPAT, and drug claims. The resources are intended for physicians, group leaders, and practice administrators evaluating their own operations.

Infectious disease billing can combine cognitive evaluation and management services with infusion administration, drug claims, OPAT, authorization requirements, and different benefit pathways. Revenue may also be affected by documentation, charge capture, payer contracts, and hospital coverage arrangements. A useful review therefore examines the complete workflow from referral and eligibility through coding, payment, denials, and accounts receivable rather than focusing only on claim submission.

Yes. Revenue leakage can occur through under-leveled visits, missed drug or administration charges, coding issues, incorrect benefit classification, short-pays, unresolved denials, or balances that are not pursued. A structured review can organize reporting by payer, service line, and provider, then trace gaps back to documentation, charge capture, workflow, or contract issues. Practices should validate findings against their own records and payer terms.

Denial management begins by categorizing denials according to their underlying causes. Relevant issues may include drug and administration coding, missing authorization, medical versus pharmacy benefit confusion, and insufficient documentation for consult services. The process can include payer-specific appeal preparation supported by clinical records, along with feedback to clinical, coding, and front-office teams so recurring problems are addressed rather than repeatedly appealed.

Payment reconciliation compares received payments with expected reimbursement for drug, administration, and evaluation and management claims. The review can flag short-pays, incorrect fee schedule application, unit discrepancies, and NDC mismatches where applicable to the claim. Findings should be documented by payer and claim type, then evaluated against the applicable contract, remittance information, coding, and supporting documentation before a dispute or recovery effort is pursued.

The resource addresses eligibility and benefits verification, medical versus pharmacy benefit classification, and prior authorization workflows for infusions, OPAT courses, and specialty drugs. Authorization is treated as both a patient-access and financial-control issue because missing approval or unclear benefit responsibility can create unreimbursed costs. Practices can use the guidance to examine tracking, documentation, payer communication, and handoffs across their own workflow.

Yes. GrowInfectiousDisease is designed for infectious disease physicians, independent infectious disease practices, group leaders, and medical practice administrators. The material is especially relevant to practices evaluating revenue streams, launching or managing infusion or OPAT services, adding providers, reviewing coverage arrangements, or investigating why collections do not align with the work being performed. Users are encouraged to apply the concepts to their own operational and financial information.

No. Its stated approach is not to publish invented rates, benchmarks, drug acquisition costs, payment rates, or margin figures. Instead, the tools and explanations help users apply their own numbers and understand the financial mechanics affecting their practice. This distinction is important because reimbursement, costs, contracts, staffing, and service-line economics can vary by practice, payer, arrangement, and operating model.